Vaccine breakthrough stops cancer returning in trial
A personalized mRNA vaccine developed by Moderna and Merck has shown promising results in preventing skin cancer from recurring in patients. The vaccine, which is tailored to individual tumors, successfully completed phase 3 clinical trials for treating melanoma. This milestone is the final step required before the drugmakers can seek approval from the FDA.
What changed
The latest development is the confirmation of the vaccine's success in phase 3 clinical trials, involving over 1,000 patients, which showed that it helped prevent the return and spread of melanoma.
Live updates
-
Vaccine breakthrough stops cancer returning in trial
A personalized mRNA vaccine developed by Moderna and Merck has shown promising results in preventing skin cancer from recurring in patients. The vaccine, which is tailored to individual tumors, successfully completed phase 3 clinical trials for treating melanoma. This milestone is the final step required before the drugmakers can seek approval from the FDA.
Why it matters
The treatment aims to stop skin cancer from returning or spreading. Researchers believe this personalized approach could eventually be applied to other types of cancer beyond melanoma. The vaccine's success in clinical trials is a significant breakthrough in the fight against cancer. Melanoma is a type of skin cancer that can be deadly if not treated promptly.
What is confirmed
- Moderna and Merck's personalized mRNA vaccine helped prevent the return and spread of melanoma in a trial involving more than 1,000 patients.
- The vaccine is tailored to individual tumors.
- The treatment aims to stop skin cancer from returning or spreading.
- Researchers believe this personalized approach could eventually be applied to other types of cancer beyond melanoma.
What to watch next
- FDA approval process for the vaccine
- Potential application of the vaccine to other types of cancer
- Long-term effects of the vaccine on patients
confidence 90%Sources used for this update (5)
- baynews9.com — New study shows personalized vaccine may help prevent skin cancer from recurring in patients
- jen.jiji.com — 'Viva Mogol!' rerun wins TV ratings, Mediterranean Games opening on the podium
- www.livemint.com — It now seems possible to vaccinate against cancer
- jen.jiji.com — Sea Watch fined by Italy, NGO attacks government: "We don't collaborate with criminals, do you?"
- bismarcktribune.com — Moderna, Merck breakthrough could usher in cancer vaccines
-
Moderna and Merck cancer vaccine clears phase 3 melanoma trials
A personalized mRNA vaccine developed by Moderna and Merck successfully completed phase 3 clinical trials for treating melanoma. The treatment aims to stop skin cancer from returning or spreading by tailoring the vaccine to individual tumors. This milestone is the final step required before the drugmakers can seek approval from the FDA. Researchers believe this personalized approach could eventually be applied to other types of cancer beyond melanoma.
Why it matters
The vaccine adapts mRNA technology previously used in Covid-19 vaccines for oncology. Moderna and Merck shares hit 52-week highs following the announcement. The treatment represents a shift toward individualized cancer therapy.
What is confirmed
- The personalized mRNA vaccine succeeded in a final-stage melanoma trial.
- The treatment targets the recurrence and spread of skin cancer.
- Moderna and Merck developed the vaccine.
Still unconfirmed
- The vaccine could be used against other types of cancer.
- The vaccine is the last step necessary before FDA approval.
What to watch next
- FDA approval decision
- Clinical trial results for other cancer types
confidence 90%Sources used for this update (4)
- www.channelnewsasia.com — CNA Explains: What we know about the Moderna, Merck breakthrough cancer vaccine
- consent.yahoo.com — Cancer vaccine prevents deadly melanoma from returning or spreading in landmark trial
- www.nationalgeographic.com — Why Scientists Say This Personalized Cancer Vaccine Could Be a Game-Changer
- www.smithsonianmag.com — A New Personalized Cancer Vaccine Could Keep Skin Cancer From Coming Back, Drugmakers Say
-
Moderna and Merck mRNA vaccine reduces skin cancer recurrence in trial
A late-stage trial of an mRNA vaccine developed by Moderna and Merck shows promise in stopping cancer from returning. The treatment specifically targets the recurrence and spread of skin cancer. Following the announcement, Moderna and Merck shares reached 52-week highs, with Moderna stock seeing significant gains. This development marks a shift for Moderna as it applies its mRNA technology from Covid-19 vaccines to oncology.
Why it matters
mRNA technology allows for the creation of vaccines tailored to specific proteins. Reducing cancer recurrence is a critical goal in oncology to prevent late-stage metastasis. This trial tests whether the vaccine can prevent skin cancer from returning after initial treatment.
What is confirmed
- Moderna and Merck developed an mRNA vaccine that shows promise in a late-stage trial.
- The vaccine is designed to reduce the recurrence and spread of skin cancer.
- Moderna and Merck stocks reached 52-week highs following the trial results.
Still unconfirmed
- Moderna stock jumped 177% in a day.
- Moderna stock soared 90%.
What to watch next
- Publication of full peer-reviewed trial data
- FDA regulatory filing for the vaccine
- Results from expanded patient cohorts
confidence 90%Sources used for this update (5)
- CNBC — Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%
- NPR — New mRNA vaccine could reduce the recurrence and spread of skin cancer
- Yahoo Finance — Why Did MRNA, MRK, TGT Stocks Jump To 52-Week Highs Today?
- BBC — Vaccine breakthrough stops cancer returning in trial
- The New York Times — From Covid to Cancer: How Moderna’s Stock Jumped 177% in a Day